In Brief: Baxter/Vimrx
This article was originally published in The Gray Sheet
Baxter/Vimrx: Firms ink definitive agreement whereby Vimrx Pharmaceuticals and Baxter's Immunotherapy Division will merge to create a new cell therapy company to market cell selection systems, such as Baxter's Isolex 300SA -- a premarket approval application for which currently is pending at FDA -- and Baxter's Isolex 300i. Both systems are marketed in Europe. As outlined in the firms' June 12 letter of intent ("The Gray Sheet" June 16, I&W-7), Vimrx will control 85% of the new entity in exchange for convertible preferred shares with a nominal value of $40 mil. and 11 mil. Vimrx common shares. Baxter will contribute $30 mil. to the company for initial operating funds, a figure $10 mil. larger than the amount Baxter had reported in June. As previously announced, Vimrx will provide $10 mil. in initial funding for the company...
You may also be interested in...
Under EU rules, once a medicinal product has been placed on the market in a country of the EEA – the EU plus Iceland, Liechtenstein and Norway
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
The national regulator is to undergo a review in 2021 as the UK begins life as a former EU member, presenting opportunities to be seized.